INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts. The conference brings together industry leaders and innovators in the rare disease space to explore the latest developments in technology and manufacturing.
https://mma.prnewswire.com/media/2310866/INOVIO_v1_Logo.jpg
Orphan Drug SummitBoston, MADate: July 16Time: 4:30-4:55pm ETPresentation: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease
About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
ContactsMedia: Jennie Willson, (267) 429-8567, communications@inovio.comInvestors: Peter Vozzo – ICR Healthcare, (443) 213-0505,investor.relations@inovio.com
https://c212.net/c/img/favicon.png?sn=PH25007&sd=2025-07-07
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302499023.html
SOURCE INOVIO Pharmaceuticals, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=PH25007&Transmission_Id=202507071605PR_NEWS_USPR_____PH25007&DateId=20250707